Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC boosted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 572.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 695,091 shares of the company's stock after purchasing an additional 591,682 shares during the quarter. Voya Investment Management LLC owned approximately 1.10% of Vera Therapeutics worth $29,395,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Huntington National Bank purchased a new stake in shares of Vera Therapeutics in the fourth quarter valued at about $26,000. AlphaQuest LLC purchased a new position in Vera Therapeutics during the fourth quarter worth $34,000. KBC Group NV lifted its position in shares of Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after acquiring an additional 1,387 shares in the last quarter. Summit Investment Advisors Inc. increased its position in Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after purchasing an additional 639 shares in the last quarter. Finally, Moors & Cabot Inc. acquired a new position in shares of Vera Therapeutics in the fourth quarter valued at approximately $220,000. Hedge funds and other institutional investors own 99.21% of the company's stock.

Vera Therapeutics Stock Up 5.4 %

Shares of NASDAQ VERA traded up $1.29 on Friday, hitting $25.04. The company had a trading volume of 494,611 shares, compared to its average volume of 749,202. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 12-month low of $18.53 and a 12-month high of $51.61. The firm has a market capitalization of $1.60 billion, a P/E ratio of -9.56 and a beta of 1.28. The business has a 50 day moving average of $24.86 and a two-hundred day moving average of $35.43.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. As a group, equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the company. Wolfe Research started coverage on Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price target for the company. Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. JPMorgan Chase & Co. cut their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. Finally, The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $64.67.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.